The NCAI-CC Technology Development Program is targeted to assist the validation and advancement of early stage medical technologies to establish commercial product potential. Funding is available for promising NHLBI-related medical technologies directed to the prevention, diagnosis, and treatment of cardiovascular, lung, blood, and sleep disorders spanning the technology range of diagnostics, diagnostic systems, devices, therapeutics, and tools, to facilitate their translation to commercialized products that improve patient care and enhance health.
Expert assistance will be provided in areas required for early technology development and project management, including commercial opportunity assessment, setting milestones, intellectual property protection, clinical and regulatory strategy, payment and reimbursement, business models, and financing.
The program operates using a semi-annual Request for Applications (RFA) to solicit medical technology projects from NCAI-CC partner institutions for funding and project support. Funds under the program are allocated to specific, measurable project development activities that are key to establishing commercial opportunity. Project scope typically encompasses work which leads to achieving critical project milestones that can be accomplished within a period of one year, and which serve to enable follow-on funding from later stage investment sources such as other federal programs (e.g., SMARTT, SBIR/STTR), other state programs (e.g. Ohio Third Frontier, Global Cardiovascular Innovation Center), venture capital or industry.
NCAI-CC partner institutions eligible for participation in the funding program are Cleveland Clinic, Case Western Reserve University, The Ohio State University, Cincinnati Children's Hospital Medical Center, the University of Cincinnati, the University of Michigan, and Northwestern University.
NCAI-CC is not currently soliciting new projects for funding consideration.
End of main page content.